Atossa Therapeutics

Atossa Therapeutics FCF Yield

The Free Cash Flow Yield of Atossa Therapeutics (ATOS) as of Nov 17, 2026 is -82.35 %. In the previous year, Free Cash Flow Yield was -58.20 % — a change of 41.50% (lower).

FCF Yield

-82.35 %

YoY

41.50%

Last updated:

Free Cash Flow Yield of Atossa Therapeutics is 2025 -82.35 % . Free Cash Flow Yield of Atossa Therapeutics was 2024 -58.20 % . It decreases by 41.50% lower compared to the previous year.

The Atossa Therapeutics FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-25.08 USD
Jan 1, 2019
-25.26 USD
Jan 1, 2020
-32.02 USD
Jan 1, 2021
-45.57 USD
Jan 1, 2022
-57.47 USD
Jan 1, 2023
-57.94 USD
Jan 1, 2024
-58.20 USD
Jan 1, 2025
-82.35 USD
The Atossa Therapeutics FCF Yield history
YEARFCF YieldYoY
-82.35 %+41.50%
-58.20 %+0.45%
-57.94 %+0.81%
-57.47 %+26.13%
-45.57 %+42.33%
-32.02 %+26.75%
-25.26 %+0.70%
-25.08 %+35.31%
-18.54 %+24.54%
-14.89 %-61.77%
-38.94 %+29.23%
-30.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Atossa Therapeutics Stock analysis

What does Atossa Therapeutics do? Atossa Therapeutics, Inc. generates revenue through the development of novel therapeutics for breast cancer and related conditions. Its pipeline includes Topical Endoxifen for reducing mammographic breast density and preventing gynecomastia in prostate cancer patients, alongside an oral formulation of endoxifen. The company also develops intraductal microcatheter technology for targeted delivery of therapeutics, including CAR-T therapy. These products target healthcare providers and pharmaceutical partners seeking innovative treatments for breast-related conditions. The company focuses on transdermal and oral delivery methods for endoxifen, addressing specific patient populations such as those with high mammographic breast density or undergoing androgen deprivation therapy. Its microcatheter technology enables direct therapeutic delivery to early breast cancer sites, positioning it for potential partnerships with oncology-focused institutions. The primary buyers are healthcare institutions and pharmaceutical companies interested in advancing breast cancer treatment options. Atossa's development of Topical Endoxifen for two distinct applications—reducing mammographic breast density and managing gynecomastia—creates dual revenue streams from the same therapeutic platform. The intraductal microcatheter technology represents a specialized delivery system for CAR-T therapies, attracting interest from biotechnology firms specializing in advanced cancer treatments. This strategic focus on niche delivery mechanisms differentiates the company in the oncology sector. Atossa Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Atossa Therapeutics stock

Free Cash Flow Yield of Atossa Therapeutics is -82.35 % in 2025.

Free Cash Flow Yield of Atossa Therapeutics changed from -58.20 % to -82.35 %, representing a 41.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Atossa Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Atossa Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Atossa Therapeutics

All Key Metrics — Atossa Therapeutics